Sign in

Private company

DICE Therapeutics, Inc.

American pharmaceutical preparations company, incorporated in Delaware1

In its 2023 annual report the company says: “We are a biopharmaceutical company leveraging our proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. We are initially focused on developing oral therapeutics against well-validated targets in immunology, with the goal of achieving comparable potency to their systemic biologic counterparts, which have demonstrated the greatest therapeutic benefit to date in these disease areas.”42 It is headquartered in South San Francisco, California.1

Last updated Oct 21, 2026.

Overview

  • IndustryPharmaceutical Preparations1
  • HeadquartersSouth San Francisco, California1
  • Incorporated inDE2
  • Business address400 East Jamie Court, Suite 300, South San Francisco, Ca 940802
  • Filer category, Emerging growth company2

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2021

-4231.4%Operating margin3
-4351.9%Net margin3
30.4%Revenue growth, 20213
-15.6%Return on equity3
0.01×Debt to equity3
-$40.0MFree cash flow3

Where the money goes

Where each dollar of revenue went, fiscal 2021

  • Research and development100¢$36.5M
  • Interest0¢$174.0K

Out of $1.1M in revenue.3 The company lost money this year.

Financial statements

Revenue43$1.1M in 2021+30% since 2020
0$500.0K$1.0M$1.5M2020: $863.0K$863.0K20202021: $1.1M$1.1M2021+30%
Operating income43-$47.6M in 2021+101% since 2020
-$60.0M-$40.0M-$20.0M02020: -$23.7M-$23.7M20202021: -$47.6M-$47.6M2021+101%
Net income43-$49.0M in 2021+106% since 2020
-$60.0M-$40.0M-$20.0M02020: -$23.7M-$23.7M20202021: -$49.0M-$49.0M2021+106%
Fiscal year201920202021
Revenue$863.0K4$1.1M3
Research and development$19.6M4$36.5M3
Operating expenses$48.7M3
Operating income-$23.7M4-$47.6M3
Interest$13.0K4$174.0K4
Net income-$23.7M4-$49.0M3
Earnings per share-$3.953
Earnings per share (diluted)-$3.953
Shares (weighted, basic)12.4M shares3
Shares (weighted, diluted)12.4M shares3

Compare DICE Therapeutics, Inc. with another company

Corporate structure

DICE Therapeutics, Inc. is part of a group headed by Eli Lilly and Company. 163 entities, 54 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of DICE Therapeutics, Inc.

  • Eli Lilly and Company Indianapolis, Indiana, United States
    • DICE Therapeutics, Inc. South San Francisco, California
    • Eli Lilly (India) Subsidiary · Gurgaon, India
    • Eli Lilly (United Kingdom) Subsidiary · Basingstoke, United Kingdom
    • ImClone Systems Subsidiary
    • Lilly (China) Subsidiary · Shanghai, People's Republic of China
    • Lilly France Subsidiary · Neuilly-sur-Seine, France
    • Adverum Biotechnologies, Inc. Subsidiary · Delaware, United States
    • Adverum NC, LLC Subsidiary · Delaware, United States
    • Akouos, Inc. Subsidiary · Delaware, United States
    • Alnara Pharmaceuticals, Inc. Subsidiary · Delaware, United States
    • Annapurna Therapeutics, Ltd. Subsidiary · Ireland
    • Aparito Espanya S.L. Subsidiary · Spain
    • Aparito LLC Subsidiary · Delaware, United States
    • ARMO Biosciences, Inc. Subsidiary · Delaware, United States
    • Avalanche Australia Pty Ltd. Subsidiary · Australia
    • Avid Radiopharmaceuticals, Inc. Subsidiary · Delaware, United States
    • CoLucid Pharmaceuticals, Inc. Subsidiary · Delaware, United States
    • Compania Farmaceutica Eli Lilly de Centro America S.A. Subsidiary · Guatemala
    • CPD 4, Inc. Subsidiary · Delaware, United States
    • Dermira, Inc. Subsidiary · Delaware, United States
    • DICE Alpha Inc. Subsidiary · Delaware, United States
    • DICE Molecules SV, Inc. Subsidiary · Delaware, United States
    • Disarm Therapeutics Inc. Subsidiary · Delaware, United States
    • Dista Ilac Ticaret Limited Sirketi Subsidiary · Turkey
    • Dista, S.A. Subsidiary · Spain
    • and 138 more

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; subsidiaries, stakes and holdings from Wikidata (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What DICE Therapeutics, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$6.3M3 Dec 31, 2022$4.9M3 Dec 31, 2021+28.3%
Accumulated depreciation$3.3M3 Dec 31, 2022$3.2M3 Dec 31, 2021+3.2%
Property and equipment, net$2.9M3 Dec 31, 2022$1.6M3 Dec 31, 2021+77.6%
Operating-lease assets (leased space)$13.1M3 Dec 31, 2022

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$461.4M3 Dec 31, 2022$115.8M3 Dec 31, 2021+298.4%
Marketable securities, current$112.8M3 Dec 31, 2022$203.5M3 Dec 31, 2021−44.6%
Debt securities available for sale$572.0M3 Dec 31, 2022$318.9M3 Dec 31, 2021+79.4%

Leadership

Who has led DICE Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Kevin Judice2021–2023

Chief financial officer

  1. Scott M. Robertson2021–2023
2025
Board members and other officers (12)

Former names

  • DiCE Molecules Holdings, LLCJul 25, 2018 to Sep 10, 20212

Timeline

  1. Aug 9, 20238-K Ended a material agreement; Completed an acquisition or sale; Listing notice or transfer19
  2. Jun 20, 20238-K Entered a material agreement; Other events20
  3. Jun 7, 20238-K Bylaws or fiscal year changed; Shareholder vote21
  4. May 11, 20238-K Results of operations22
  5. Mar 15, 20238-K Results of operations23
  6. Feb 10, 20238-K Executive or director change24
  7. Nov 17, 20228-K Bylaws or fiscal year changed25
  8. Nov 9, 20228-K Results of operations26
  9. Oct 13, 20228-K Entered a material agreement; Results of operations; Other events27
  10. Oct 11, 20228-K Other events28
  11. Aug 11, 20228-K Results of operations29
  12. Jun 28, 20228-K Entered a material agreement; Unregistered sale of shares30
  13. Sep 14, 2021New chief executive Kevin Judice becomes CEO7

Calendar

When it reported results

  1. May 11, 2023Reported quarterly or annual results22
  2. Mar 15, 2023Reported quarterly or annual results23
  3. Nov 9, 2022Reported quarterly or annual results26
  4. Oct 13, 2022Reported quarterly or annual results27
  5. Aug 11, 2022Reported quarterly or annual results29
  6. May 12, 2022Reported quarterly or annual results31
  7. Mar 21, 2022Reported quarterly or annual results32
  8. Nov 12, 2021Reported quarterly or annual results33

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

119 filings to the SEC since October 2021: 2 annual reports, 6 quarterly reports, 19 major events, 46 insider forms, 15 large holders, 31 other. The latest 20:

  1. Aug 21, 202315-12G EDGAR
  2. Aug 10, 2023EFFECT EDGAR
  3. Aug 9, 20234 FORM 4 SUBMISSION EDGAR
  4. Aug 9, 20234 FORM 4 SUBMISSION EDGAR
  5. Aug 9, 20234 FORM 4 SUBMISSION EDGAR
  6. Aug 9, 20234 FORM 4 SUBMISSION EDGAR
  7. Aug 9, 20234 FORM 4 SUBMISSION EDGAR
  8. Aug 9, 20234 FORM 4 SUBMISSION EDGAR
  9. Aug 9, 20234 FORM 4 SUBMISSION EDGAR
  10. Aug 9, 20234 FORM 4 SUBMISSION EDGAR
  11. Aug 9, 20234 FORM 4 SUBMISSION EDGAR
  12. Aug 9, 20234 FORM 4 SUBMISSION EDGAR
  13. Aug 9, 2023S-8 POS EDGAR
  14. Aug 9, 2023S-8 POS EDGAR
  15. Aug 9, 2023S-8 POS EDGAR
  16. Aug 9, 2023POSASR EDGAR
  17. Aug 9, 2023POS AM EDGAR
  18. Aug 9, 20238-K EDGAR
  19. Aug 9, 2023SC 14D9/A EDGAR
  20. Aug 9, 20234 OWNERSHIP DOCUMENT EDGAR

The 119 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

18 open-market trades by officers, directors and large owners since October 2021: 7 buys and 11 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jun 22, 2023Northpond Ventures II, LP10% ownerSale2,492,871$46.50$115.9MForm 4
Jun 1, 2023Jacobsen John R.CSOSale18,750$30.53$572.4KForm 4
May 5, 2023SCHELLER RICHARD HDirectorSale84,097$38.51$3.2MForm 4
May 3, 2023Robertson Scott M.CFO & CBOSale18,750$36.55$685.3KForm 4
May 3, 2023Timothy LuCMOSale10,000$36.54$365.4KForm 4
May 3, 2023Judice KevinCEOSale13,698$36.50$500.0KForm 4
Apr 18, 2023Jacobsen John R.CSOSale16,392$30.08$493.1KForm 4
Mar 31, 2023Jacobsen John R.CSOSale773$30.00$23.2KForm 4
Mar 30, 2023RA Capital Nexus Fund II, L.P.Buy195,997$28.74$5.6MForm 4
Mar 29, 2023Jacobsen John R.CSOSale1,094$30.00$32.8KForm 4
Mar 29, 2023RA Capital Nexus Fund II, L.P.Buy66,369$29.38$1.9MForm 4
Mar 28, 2023Jacobsen John R.CSOSale500$30.09$15.0KForm 4
Mar 28, 2023RA Capital Nexus Fund II, L.P.Buy246,779$29.24$7.2MForm 4
Mar 27, 2023RA CAPITAL MANAGEMENT, L.P.Buy151,132$27.48$4.2MForm 4
Mar 24, 2023RA CAPITAL MANAGEMENT, L.P.Buy192,335$26.87$5.2MForm 4
Mar 23, 2023RA CAPITAL MANAGEMENT, L.P.Buy155,089$26.67$4.1MForm 4
Mar 17, 2023Scopa James PaulDirectorSale10,000$29.05$290.5KForm 4
Oct 17, 2022Kolchinsky PeterBuy1,640,000$36.50$59.9MForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How DICE Therapeutics, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARDICE Therapeutics, Inc.1
  • CIK0001645569
  • Employer ID (EIN)47-22862441
  • Filer status<br>emerging growth company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 301
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • Business address400 East Jamie Court, Suite 300, South San Francisco, CA 940801
  • Phone650-566-14021
  • Shares outstanding47,790,092 as of Jul 31, 20236
  • Public float$436.6M as of Jun 30, 20223
  • On EDGAR sinceJun 18, 20151
  • Filings173 in all: 4 (52), 8-K (19), 3 (14), SC 13D/A (7), 10-Q (6), SC 13G (5), 144 (4), CORRESP (4)1
    All 45 form types

    D (4), EFFECT (3), S-8 (3), S-8 POS (3), SC 13D (3), SC 13G/A (3), SC 14D9/A (3), SC TO-T/A (3), UPLOAD (3), 10-K (2), 424B5 (2), DEF 14A (2), DEFA14A (2), S-1/A (2), SEC STAFF LETTER (2), 15-12G (1), 25-NSE (1), 424B4 (1), 5 (1), 8-A12B (1), ARS (1), CERT (1), DRS (1), DRS/A (1), DRSLTR (1), FWP (1), POS AM (1), POSASR (1), PRE 14A (1), S-1 (1), S-1MEF (1), S-3 (1), S-3ASR (1), SC 14D9 (1), SC TO-C (1), SC TO-T (1), SC14D9C (1)

  • Latest filingsAnnual report (10-K) Mar 15, 2023
    Quarterly report (10-Q) Aug 8, 2023
    Proxy statement (DEF 14A) Apr 26, 2023
    Latest 8-K (8-K) Aug 9, 2023

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
    SEC EDGAROther events
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42